Rapport Therapeutics Inc.
Clinical trials sponsored by Rapport Therapeutics Inc., explained in plain language.
A biopharmaceutical company developing precision medicines for neurological disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New pill aims to curb focal seizures in adults
Disease control Recruiting nowThis phase 3 study tests whether an investigational drug called RAP-219 can safely reduce the number of focal seizures in adults with epilepsy. About 312 participants will take either a low or medium dose of RAP-219 or a placebo pill daily. The main goal is to see if the drug low…
Phase 3 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New epilepsy drug RAP-219 enters final testing phase
Disease control Recruiting nowThis study tests an experimental drug called RAP-219 in 333 adults with focal seizures (a type of epilepsy). The goal is to see if the drug safely reduces how often seizures happen compared to a placebo. Participants must be 18-75, have had focal epilepsy for at least 2 years, an…
Phase 3 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for tough seizures: Long-Term safety trial launches
Disease control Recruiting nowThis study tests the long-term safety of an experimental drug called RAP-219 in 30 adults whose focal seizures do not respond well to current treatments. Participants must have already completed a related earlier study. The goal is to see if RAP-219 remains safe and helps reduce …
Phase 2 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC